[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a87c6b7713f581fc9283b5b380be76ca6",
    "date": "2026-05-06",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "IRLAB_Q1_2026_SWE_Final.pdf",
    "text_chars": 64339,
    "sha256": "505b54a29eaa6a93bf41402ed03679fe073606a2cd013d7c22f34f3f8c322dd5",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 64339
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a08f90ae9f03475896d18a02f6d5b699a",
    "date": "2026-04-29",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "IRLAB_AR_2025_Final.pdf",
    "text_chars": 305823,
    "sha256": "b398d00744eb567bb06f1835db007e9b595168a464cf4dce9f6d11f192e85b88",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 173738
      },
      {
        "number": 2,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 132083
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a48787c44f5366998963665e14d608ab4",
    "date": "2026-02-25",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_FINAL.pdf",
    "text_chars": 66724,
    "sha256": "8917d995eeda295c1c407c7b77047790a2f1ba2ae93c17920902bb736a8bef8d",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 66724
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a3ba9467d849249338ab8792cb61df4b3",
    "date": "2025-10-29",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "IRLAB_Q3_2025_SVE.pdf",
    "text_chars": 64430,
    "sha256": "928ee49df5c30450024cec6bdc2270377b083d96c0a99d932cacadee38b4e448",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 64430
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a31d3ebef0648ca7e0eeb33d8e7266b8b",
    "date": "2025-08-27",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "IRLAB_Q2_FINAL_SE.pdf",
    "text_chars": 60171,
    "sha256": "03c14f5469d2b82ba9f7cf702eac7ad9c91f0bee2d0a9de930f2dc7d58199329",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 60171
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a1f353db402d76b5479bf0040f1c3cce6",
    "date": "2025-05-07",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "IRLAB_Q1_FINAL_SE.pdf",
    "text_chars": 59022,
    "sha256": "5ac7796a165c826ffb3920a3b34fb66ee08a1033afdbd750f5536ef4e1a5f478",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 59022
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac4a1932700de0a546597011645bdf448",
    "date": "2025-04-25",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "IRLAB_Arsredovisning_2025_Lowres.pdf",
    "text_chars": 290897,
    "sha256": "bc8fcbfb01a527e6bdd643048fa5dbe5dd3801df7ba92c594be73d58c1254748",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 173259
      },
      {
        "number": 2,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 117636
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac65fdb073394f8e0661529ce41b2a0d3",
    "date": "2025-02-12",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "IRLAB_Q4_SVE_2025_02_12.pdf",
    "text_chars": 59877,
    "sha256": "cf9867387056374714f0d929e163622e53c4d747347a02e5ba4a70675520bc10",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 59877
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aa88601b14548120afa4692d054312648",
    "date": "2024-10-30",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "IRLAB_Q3_2024_SVE.pdf",
    "text_chars": 61821,
    "sha256": "c7a90c457983af2c8fc9db92d1c51ddf7ebc39a3d34568046704eecbcfaec9f8",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 61821
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a8fe2f4726a5dbc7f4f772724efc021d6",
    "date": "2024-07-10",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "IRLAB_Q2_2024_SVE.pdf",
    "text_chars": 54432,
    "sha256": "7261d5991584403d422756691cb5fae45edb9e4dc2010a530f649262f8534780",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 54432
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a283d252335a38071c82196bacb1f08ba",
    "date": "2024-05-08",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "IRLAB_Q1_24_Final_SVE.pdf",
    "text_chars": 53733,
    "sha256": "fe521fb4271cf01c8b83263caf2e6ff835645a69ac731cbe1acad4a4d65ab8a0",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 53733
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a680177f5f7902bb9c2b64c8ac8783bcc",
    "date": "2024-04-29",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "IRLAB_Arsredovisning_2023.pdf",
    "text_chars": 288962,
    "sha256": "8376ba43757e9f2515a2cb30dca7357684e494cf3ba8e5bc3bceb1784e900be5",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 178416
      },
      {
        "number": 2,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 110544
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/adda82490b9cd45873daa2c13d1a42a2f",
    "date": "2024-02-07",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "IRLAB_Bokslutskommunike_2023.pdf",
    "text_chars": 56219,
    "sha256": "909162dbd9614fee71d5e70483759de69c87753a4fb3c235a0008e0f84bb31eb",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 56219
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a9a35737af26033f7b36b6809e73cb2f5",
    "date": "2023-10-25",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "IRLAB_Delarsrapport_Q3_2023.pdf",
    "text_chars": 54885,
    "sha256": "618eb6cb64f39e88e7d435f572de1f79e8103b1f7ee2a9f3dd48042ccdef06e3",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 54885
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a06944ca44a858fbd57afb56e67641dcc",
    "date": "2023-08-30",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "IRLAB_Delarsrapport_Q2_2023.pdf",
    "text_chars": 56836,
    "sha256": "d658b6246c4a52f07c9bdd58ef5155ff9c73f18772353d15b5511f82599d5395",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 56836
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a35f1abb0bd3293f977d871a5c05f21b9",
    "date": "2023-05-10",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "IRLAB_Delarsrapport_Q1_2023.pdf",
    "text_chars": 65900,
    "sha256": "1dc1c34123f46504928637e587beda0a970ed7ff02c96aed652de0bbde749a2a",
    "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 65900
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/irlab-therapeutics",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 12861,
    "sha256": "04f334cc5c71867ede296ccddb4d0d58ccbb3892324592c834b595095590ff0e",
    "url": "/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 12861
      }
    ]
  }
]